Compare AUUD & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUUD | VNRX |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 6.5M |
| IPO Year | 2020 | 2012 |
| Metric | AUUD | VNRX |
|---|---|---|
| Price | $1.34 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.67 |
| AVG Volume (30 Days) | 665.7K | ★ 9.9M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,727,384.00 |
| Revenue This Year | N/A | $355.66 |
| Revenue Next Year | N/A | $849.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 40.04 |
| 52 Week Low | $0.51 | $0.13 |
| 52 Week High | $10.10 | $3.26 |
| Indicator | AUUD | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 26.36 |
| Support Level | N/A | $0.23 |
| Resistance Level | N/A | $0.27 |
| Average True Range (ATR) | 0.00 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 15.48 |
Auddia Inc is a United States-based company. It operates through its proprietary AI platform for audio and is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. The group Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Its flagship audio superapp, called faidr, delivers multiple industry firsts, including: Ad-free listening on any AM/FM radio station, Content skipping across any AM/FM station, One-touch skipping of entire podcast ad breaks, and Integrated artist discovery experiences.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.